U.S. markets close in 2 hours 11 minutes

Eargo, Inc. (EAR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.87-1.20 (-3.44%)
As of 1:48PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.07
Open35.28
Bid33.71 x 2900
Ask33.96 x 1000
Day's Range32.58 - 36.70
52 Week Range32.58 - 43.80
Volume436,296
Avg. Volume3,781,700
Market Cap1.19B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Yahoo Finance Video

      Eargo CEO on company outlook amid NASDAQ listing

      Christian Gormsen, Eargo CEO, joins Yahoo Finance’s The First Trade with Alexis Christoforous and Brian Sozzi to discuss the company's public debut and much more.

    • Barrons.com

      Hearing-Aid Maker Eargo Soars 87% in Its First Trading Day

      Eargo is one of several companies go public Friday. Praxis Precision Medicines, Tarsus Pharmaceuticals, and Aligos Therapeutics are also on tap to commence trading.

    • GlobeNewswire

      Eargo, Inc. Announces Upsized Pricing of Initial Public Offering

      SAN JOSE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of $18.00 per share. In connection with the offering, Eargo has granted the underwriters a 30-day option to purchase up to an additional 1,177,777 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on October 16, 2020 under the ticker symbol “EAR.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Eargo, are expected to be approximately $141.3 million, excluding any exercise of the underwriters’ option to purchase additional shares. The closing of the offering is expected to occur on October 20, 2020, subject to satisfaction of customary closing conditions. J.P. Morgan and BofA Securities acted as lead book-running managers and as representatives of the underwriters for the offering. Wells Fargo Securities and William Blair acted as co-managers for the offering.The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus‐eq_fi@jpmorgan.com or by telephone at (866) 803‐9204, or from BofA Securities, NC1‐004‐03‐43, 200 North College Street, 3rd Floor, Charlotte, NC 28255‐0001, Attention: Prospectus Department, by email at dg.prospectus_requests@bofa.com.A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 15, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About EargoEargo is a medical device company dedicated to improving the quality of life of people with hearing loss. Eargo developed the Eargo solution to create a hearing aid that consumers actually want to use. Eargo’s innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost.Investor Contact Nick Laudico Vice President of Investor Relations ir@eargo.comMedia Contact Aaron Murphy eargo@edelman.com